Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

Chronic myeloid leukemia stem cells.

Kavalerchik E, Goff D, Jamieson CH.

J Clin Oncol. 2008 Jun 10;26(17):2911-5. doi: 10.1200/JCO.2008.17.5745. Review.

PMID:
18539972
2.

Getting to the stem of chronic myeloid leukaemia.

Savona M, Talpaz M.

Nat Rev Cancer. 2008 May;8(5):341-50. doi: 10.1038/nrc2368. Review.

PMID:
18385684
3.

Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.

Valent P, Deininger M.

Leuk Lymphoma. 2008 Apr;49(4):604-9. doi: 10.1080/10428190801923212. Review.

PMID:
18398718
4.

Mathematical models of cancer stem cells.

Michor F.

J Clin Oncol. 2008 Jun 10;26(17):2854-61. doi: 10.1200/JCO.2007.15.2421. Review.

PMID:
18539964
5.

Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Sato T, Goyama S, Kataoka K, Nasu R, Tsuruta-Kishino T, Kagoya Y, Nukina A, Kumagai K, Kubota N, Nakagawa M, Arai S, Yoshimi A, Honda H, Kadowaki T, Kurokawa M.

Oncogene. 2014 Oct 16;33(42):5028-38. doi: 10.1038/onc.2014.108. Epub 2014 Apr 21.

6.

Selective elimination of leukemia stem cells: hitting a moving target.

Crews LA, Jamieson CH.

Cancer Lett. 2013 Sep 10;338(1):15-22. doi: 10.1016/j.canlet.2012.08.006. Epub 2012 Aug 17. Review.

PMID:
22906415
7.

Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia.

Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan AG.

Leuk Lymphoma. 2010 Nov;51(11):2103-11. doi: 10.3109/10428194.2010.520774. Epub 2010 Oct 7.

PMID:
20929330
8.

Chronic myeloid leukemia stem cell biology.

Crews LA, Jamieson CH.

Curr Hematol Malig Rep. 2012 Jun;7(2):125-32. doi: 10.1007/s11899-012-0121-6.

9.

Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.

Michor F.

Trends Pharmacol Sci. 2007 May;28(5):197-9. Epub 2007 Apr 6.

PMID:
17412430
10.

New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

Stefanachi A, Leonetti F, Nicolotti O, Catto M, Pisani L, Cellamare S, Altomare C, Carotti A.

Curr Cancer Drug Targets. 2012 Jun;12(5):571-96. Review.

PMID:
22414010
11.

beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.

Hu Y, Chen Y, Douglas L, Li S.

Leukemia. 2009 Jan;23(1):109-16. doi: 10.1038/leu.2008.262. Epub 2008 Sep 25.

PMID:
18818703
12.

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.

Salati S, Salvestrini V, Carretta C, Genovese E, Rontauroli S, Zini R, Rossi C, Ruberti S, Bianchi E, Barbieri G, Curti A, Castagnetti F, Gugliotta G, Rosti G, Bergamaschi M, Tafuri A, Tagliafico E, Lemoli R, Manfredini R.

Oncotarget. 2017 Jul 25;8(30):49451-49469. doi: 10.18632/oncotarget.17706.

13.

[Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].

Akhlynina TV, Gerasimova LP, Sarkisian GP, Borovkova TV, Dukhovenskaia EA, Manakova TE, Nań≠denova NM, Timofeev AM, Grineva NI.

Tsitologiia. 2007;49(10):889-900. Russian.

PMID:
18074781
14.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

15.

Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies.

Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C.

Leukemia. 2003 Jul;17(7):1211-62. Review.

PMID:
12835715
16.

The chronic myeloid leukemia stem cell.

Nicholson E, Holyoake T.

Clin Lymphoma Myeloma. 2009;9 Suppl 4:S376-81. doi: 10.3816/CLM.2009.s.037. Review.

PMID:
20007106
17.

Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.

Ali MA.

Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1. Review.

PMID:
27220498
18.

The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.

Williams RT, Sherr CJ.

Cold Spring Harb Symp Quant Biol. 2008;73:461-7. doi: 10.1101/sqb.2008.73.039. Epub 2008 Nov 21. Review.

PMID:
19028987
19.

Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.

Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M, Hattori M, Minato N.

Cancer Res. 2006 Oct 15;66(20):9967-76.

20.

Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.

Fang B, Zheng C, Liao L, Han Q, Sun Z, Jiang X, Zhao RC.

Blood. 2005 Apr 1;105(7):2733-40. Epub 2004 Dec 9.

Supplemental Content

Support Center